Press Releases

LyGenesis Announces First Patient Dosed in its ...

PITTSBURGH, April 2, 2024 /PRNewswire/ -- LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a...

LyGenesis Announces First Patient Dosed in its ...

PITTSBURGH, April 2, 2024 /PRNewswire/ -- LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a...

Chrysea Acquires Rodon Biologics to Strengthen ...

Chrysea Acquires Rodon Biologics to Strengthen Capabilities in Synthetic Biology and Biopharmaceutical Products Development. 13 February 2024 Chrysea acquires operational capability, skills and know-how, to drive capital-efficiency. Chrysea accesses a...

Chrysea Acquires Rodon Biologics to Strengthen ...

Chrysea Acquires Rodon Biologics to Strengthen Capabilities in Synthetic Biology and Biopharmaceutical Products Development. 13 February 2024 Chrysea acquires operational capability, skills and know-how, to drive capital-efficiency. Chrysea accesses a...

Chrysea and Chalmers University Partner for Development of Benzylisoquinoline Alkaloids for Human and Animal Healthcare

Chrysea and Chalmers University Partner for Dev...

Leveraging synthetic biology and data analytics to unlock the sustainable development of high-value bioactives with unparalleled purity and volume at scale. DUBLIN, IRELAND AND CANTANHEDE, PORTUGAL, February 9, 2024 /EINPresswire.com/...

Chrysea and Chalmers University Partner for Dev...

Leveraging synthetic biology and data analytics to unlock the sustainable development of high-value bioactives with unparalleled purity and volume at scale. DUBLIN, IRELAND AND CANTANHEDE, PORTUGAL, February 9, 2024 /EINPresswire.com/...

LyGenesis Raises $19M in Series A-2 Funding Led...

Funds will enable the completion of the ongoing Phase 2a clinical trial growing ectopic livers for patients with end stage liver disease and advance LyGenesis's pipeline of cell therapies  ...

LyGenesis Raises $19M in Series A-2 Funding Led...

Funds will enable the completion of the ongoing Phase 2a clinical trial growing ectopic livers for patients with end stage liver disease and advance LyGenesis's pipeline of cell therapies  ...

Serina Therapeutics and AgeX Therapeutics Enter...

Merger to result in NYSE American-listed company focused on developing therapeutics based on Serina’s proprietary POZ Platform™ delivery technology Lead program of the combined company will be SER-252 (POZ-apomorphine) for the...

Serina Therapeutics and AgeX Therapeutics Enter...

Merger to result in NYSE American-listed company focused on developing therapeutics based on Serina’s proprietary POZ Platform™ delivery technology Lead program of the combined company will be SER-252 (POZ-apomorphine) for the...

LyGenesis and Imagine Pharma Announce Joint Res...

PITTSBURGH, April 11, 2023 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1)...

LyGenesis and Imagine Pharma Announce Joint Res...

PITTSBURGH, April 11, 2023 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1)...